What happened
HLB Pharmaceutical updated its previously filed consolidated results for FY2025: revenue of US$140M (+50% year on year), operating profit of US$726K (−27.8% year on year) and net income of US$3.12M (+126.3% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$140M |
|---|---|
| Revenue vs a year earlier | +50% |
| Operating profit | US$726K |
| Net income | US$3.12M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-10, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260310901170 → open original filing |
Versions of this filing
- 2026-02-02Original
- 2026-03-10Amendment 1 (this page)
Source: DART. Information only, not investment advice.